MiNK Therapeutics announced a Phase 2 trial evaluating a novel iNKT cell therapy combination for advanced gastroesophageal cancer at ASCO GI.
Quiver AI Summary
MiNK Therapeutics, Inc. announced that it will present at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, discussing its innovative iNKT cell therapies aimed at treating cancer. CEO Dr. Jennifer Buell emphasized the crucial role of iNKT cells in enhancing immune response against advanced cancers, particularly through their combination with Agenus’ botensilimab and balstilimab, which aim to reshape the tumor environment. The ongoing Phase 2 trial, investigating the combination of agenT-797 iNKT cells, botensilimab, balstilimab, along with ramucirumab and paclitaxel in patients with advanced gastroesophageal cancers, shows early signs of effectiveness and tolerability, particularly in gastric cancer patients. MiNK expects to provide further updates on this study later in 2025.
Potential Positives
- MiNK Therapeutics will present significant findings at the prestigious ASCO GI Symposium, highlighting their commitment to advancing cancer therapies.
- The Phase 2 trial of the novel combination therapy shows promising signals of tolerability and activity, particularly in patients with relapsed/refractory gastric cancer, indicating potential efficacy of their treatment approach.
- Positive data from a prior Phase I trial demonstrate long-term durable responses in patients with various types of cancer, strengthening the company's therapeutic credibility.
- The company's focus on scalable and reproducible manufacturing for off-the-shelf delivery could enhance accessibility and market potential for their iNKT cell therapies.
Potential Negatives
- The announcement of future results from the Phase 2 study leaves investors with uncertainty about the current status and effectiveness of the therapies being tested.
- The reliance on forward-looking statements suggests that the company is preemptively managing expectations, indicating potential risks that could hinder progress.
- The caution not to place considerable reliance on the forward-looking statements may undermine investor confidence in the company's outlook and claims about its therapies.
FAQ
What is the focus of MiNK Therapeutics' latest clinical trial?
MiNK Therapeutics is evaluating a novel combination therapy for advanced gastroesophageal cancer in their Phase 2 clinical trial.
When is MiNK Therapeutics presenting at the ASCO GI Symposium?
The presentation is scheduled for January 23, 2025, from 11:30 AM to 1:00 PM PST.
What does the combination therapy include?
The therapy includes agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel for treating advanced GE adenocarcinoma.
How can I access the presentation details?
The presentation details will be available on the MiNK Therapeutics publications page during the presentation session.
What types of cancers has the Phase I trial targeted?
The Phase I trial has shown effects in testicular, appendiceal, lung, and gastric cancers among others.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INKT Hedge Fund Activity
We have seen 9 institutional investors add shares of $INKT stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC removed 21,154 shares (-16.5%) from their portfolio in Q3 2024, for an estimated $15,865
- CAPTRUST FINANCIAL ADVISORS removed 20,407 shares (-57.1%) from their portfolio in Q3 2024, for an estimated $15,305
- GOLDMAN SACHS GROUP INC removed 17,561 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $13,170
- MILLENNIUM MANAGEMENT LLC removed 13,121 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $9,840
- TWO SIGMA SECURITIES, LLC added 11,937 shares (+inf%) to their portfolio in Q3 2024, for an estimated $8,952
- GREENWICH WEALTH MANAGEMENT LLC added 10,805 shares (+inf%) to their portfolio in Q3 2024, for an estimated $8,103
- TOWER RESEARCH CAPITAL LLC (TRC) removed 4,920 shares (-55.0%) from their portfolio in Q3 2024, for an estimated $3,690
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium in San Francisco, California.
“INKT cells play a pivotal role in reconstituting lymphocytes, establishing a robust and responsive immune environment to address the complexities of advanced cancers. Agenus’ botensilimab/balstilimab combination (BOT/BAL) amplifies this effect by enhancing T-cell priming, eliminating immunosuppressive regulatory cells, and fostering long-term immune memory. This novel multi-immune combination treats the immune system itself, fundamentally reshaping the tumor environment to make disease biologically unsustainable,” said Dr. Jennifer Buell, Chief Executive Officer at MiNK Therapeutics. “We look forward to sharing further results from this study later this year.”
Phase 2 AgenT-797 plus BOT/BAL in Combination with Ramucirumab and Paclitaxel in Patients with Previously Treated, Unresectable or Metastatic Gastroesophageal Cancers (Abstract TPS515)
- This investigator-initiated, single-arm Phase 2 trial, conducted at Memorial Sloan Kettering Cancer Center (NCT06251793), evaluates the novel combination of agenT-797 (iNKT cells), botensilimab, balstilimab, ramucirumab, and paclitaxel in advanced GE adenocarcinoma patients who have received at least one prior line of therapy.
- Data from the prior Phase I trial (NCT05108623) demonstrated long-term, durable responses and tolerability in PD-1 refractory relapsed/refractory cancers, including testicular, appendiceal, lung, and gastric cancers. Notably, gastric cancer patients exhibited significant clinical and immunologic responses, including robust T cell infiltration and expansion compared to non-responders.
-
This novel, multi-immunologic combination demonstrated signals of tolerability and activity in patients with relapsed/refractory gastric cancer. MiNK plans to provide a clinical update from the ongoing Phase II study in the second half of 2025.
The presentation will be available on the publications page of the MiNK website at the start of the scheduled presentation session at https://minktherapeutics.com/publications/ .
Presentation Details
Abstract Title:
A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
Abstract Number:
TPS515
Presenting Author:
Dr. Samuel Cytryn
Session:
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Session Date and Time:
1/23/2025, 11:30 AM-1:00 PM PST
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
[email protected]
Media Contact
781-674-4428
[email protected]